A Population-Based Registry Study of Extended Bisphosphonate Use: Minimal Shift After Landmark Publications About Shorter Treatment Duration
Authors' conclusion
Landmark studies leading to more limited bisphosphonate courses may have slightly reduced longer-term treatment, but up to one-third of adherent patients in the modern era still receive continuous bisphosphonate therapy for >10 years.
Study context
- Population
- Women aged >50 years with Bone Mineral Density (BMD) between 1995 and 2018, oral bisphosphonate first prescribed for >90 days with adherence >75% in the first yearmean follow-up 8.8 (1.3) years
- Participants
- 2,991 women
- Exposure
- Therapy start 1998-2004 vs 2005-2012
- Outcome
- Percentage of bisphosphonate users beyond 5 years, earlier vs later era
Methodological detailsManitoba BMD Registry linked to provincial pharmacy data
- Manitoba BMD Registry linked to provincial pharmacy data
Main finding
As reported in the abstract
Bisphosphonate use beyond 5 years, earlier (1998-2004 starts) vs later (2005-2012 starts) era
Completed 5 years, earlier vs later era
74.4% vs 70.2%
Treated ≥6 years, earlier vs later era (p < 0.0001)
68.0% vs 60.5%
Treated >10 years, earlier vs later era (p = 0.08)
46.6% vs 33.5%
Observational data: associations, not effects.
Further findings
Continuous oral bisphosphonate duration, whole cohort
- >5 years
- 64.9%
- >10 years
- 41.9%
Medication possession rate
- Medication possession rate in every year of therapy
- >79%
Original publication
A Population-Based Registry Study of Extended Bisphosphonate Use: Minimal Shift After Landmark Publications About Shorter Treatment Duration. J Bone Miner Res. Published 13 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →